Company Active LTD

Company profile

Oppilotech Ltd

Home - Navigating Biology, Discovering Drugs

Oppilotech Ltd is a UK company with status active founded in 2014 based in London.

CRN
08835326
Founded
2014
Age
12

Overview

Legal name
OPPILOTECH LTD
Region
London
Registered address
LONDON BIOSCIENCE INNOVATION CENTRE
2 ROYAL COLLEGE STREET
LONDON
NW1 0NH
Insolvency history
No

Latest accounts

Financial period: 1 Feb 2024 to 31 Jan 2025

FULLACCOUNTS
Turnover
Unknown
Profit / Loss
-£124,618
Employees
4

Company events

Reference milestones and recent Companies House filing stream events.

6 events
25 Feb
2027

Confirmation statement due

Confirmation Due

Next confirmation statement due date

31 Oct
2026

Accounts due

Accounts Due

Next accounts due date

11 Feb
2026

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Jan
2025

Accounts filed

Accounts

Last accounts made up date

05 Nov
2024

Accounts With Accounts Type Total Exemption Full

Accounts Analysed

AA | Transaction MzQ0MjAwNzUyMmFkaXF6a2N4 | Paper/PDF filed

Published 06 Nov 2024 07:18

07 Jan
2014

Incorporated

Inception

Company registered at Companies House

Public funding

5 awards
First funded
2017
Funded years
2017, 2018, 2019, 2020, 2023
Age at first award
3 years

Projects

2023 Collaborative R&D Lead participant

Development of a First-in-Class Antibiotic Targeting the Biosynthesis of the Outer Envelope of Gram-Negative Bacteria

1 Oct 2023 to 31 May 2025

Awarded
£497,278
Total cost £710,397

Effective treatment of bacterial infections is an essential component of modern medicine. To that end, antibiotics have played a central role in saving millions of lives. Antibiotic resistance - when bacteria change so that antibiotics no longer work, is growing at a dangerously high rate and poses one of the greatest public health threats of our time. Of...

2020 Feasibility Studies Lead participant

Development of Key Technologies for Real-Time Diagnosis, Surveillance and Intervention of Resistant-Bacterial Infections Based on Nanopore Sequencing

1 Jun 2020 to 30 Nov 2020

Awarded
£60,200
Total cost £60,200

no public description

2019 Collaborative R&D Lead participant

Development of Key Technologies for Real-Time Diagnosis, Surveillance and Interventionof Resistant-Bacterial Infections Based on Nanopore Sequencing

1 May 2019 to 30 Sep 2022

Awarded
£205,310
Total cost £293,000

The proposed project aims to tackle two of the major hurdles in the fight against AMR, new drugs and new diagnostics. The new diagnostics will utilise cutting edge UK technology (Oxford Nanopore sequencing) to provide test results with unprecedented depth of information within 6 hours as opposed to the current technologies which routinely take 24-48 hours...

2018 Feasibility Studies Lead participant

Development of a complete pathway model for the synthesis of the gram negative cell

1 Jan 2018 to 31 Dec 2018

Awarded
£70,000
Total cost £100,000

It is predicted that within the next 33 years, deaths attributable to antibiotic resistant bacteria will outnumber those caused by cancer. This problem is compounded by the lack of both the discovery and development of novel antimicrobial molecules. Of particular concern are the resistance levels exhibited by the Gram -ve bacterial species such as E.coli,...

2017 Feasibility Studies Lead participant

Development of a Novel Wall Teichoic Acid Inhibitor as an Oral Combination Therapy for MRSA

1 Aug 2017 to 30 Apr 2018

Awarded
£135,120
Total cost £193,028

The emergence of multi-drug resistant bacteria is now a major public health concern. Reports from the Wellcome Trust, World Health Organization and the Chief Medical Officer of the United Kingdom have highlighted the urgent need for the identification and development of new antibiotics, especially those with novel modes of action. Antibiotic resistance wi...

Product types

Collaborative R&D Feasibility Studies